Stockreport

Oyster Point Pharma Announces Positive Top-Line Results From the Phase 1 “ZEN” Study of Its Lead Nicotinic Agonist Nasal Spray in Development for the Treatment of Dry Eye Disease

Oyster Point Pharma, Inc. - common stock  (OYST) 
Last oyster point pharma, inc. - common stock earnings: 2/27 04:01 pm Check Earnings Report
PDF PRINCETON, N.J., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, devel [Read more]